ICI 215,001 hydrochloride
Discontinued ProductICI 215,001 hydrochloride (Cat. No. 0929) has been withdrawn from sale for commercial reasons.
The active metabolite of ZD 7114 (Cat. No. 0930).
Sold with the permission of AstraZeneca UK Ltd.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
References are publications that support the biological activity of the product.
How (1993) β3Adrenergic agonists. Drugs Future 18 529
View Related Products by Product Action
Keywords: ICI 215,001 hydrochloride, ICI 215,001 hydrochloride supplier, β3-adrenoceptor, b3-adrenoceptor, β3-adrenergic, b3-adrenergic, agonists, Receptors, ICI215001, hydrochloride, AstraZeneca, Adrenergic, Beta-3, 0929, Tocris Bioscience
2 Citations for ICI 215,001 hydrochloride
Citations are publications that use Tocris products. Selected citations for ICI 215,001 hydrochloride include:
Suárez et al (2014) Oleoylethanolamide enhances β-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat. Dis Model Mech 7 129 PMID: 24159189
Littmann et al (2015) Recruitment of β-arrestin 1 and 2 to the β2-adrenoceptor: analysis of 65 ligands. PLoS One 355 183 PMID: 26306764
Reviews for ICI 215,001 hydrochloride
There are currently no reviews for this product. Be the first to review ICI 215,001 hydrochloride and earn rewards!
Have you used ICI 215,001 hydrochloride?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.